i-SENS, Inc.
Financials
Valuation Metrics
i-SENS, Inc.'s Market Cap is ₩4776B. At end of 2025 it was ₩4702B. Ranked #478 of 2,421 in KR market (top 20%), #175 of 1,640 on KOSDAQ (top 11%), #11 of 96 in Health Care Equipment & Services (top 11%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 477.61B KRW | KR#478/2,421 Sec#11/96 |
| Revenue | 326.19B KRW | KR#797/2,421 Sec#8/96 |
| Net Income | -4.11B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 599.15B KRW | KR#686/2,421 Sec#9/96 |
| Net Assets | 363.98B KRW | KR#640/2,421 Sec#9/96 |
| Employees | 904 | KR#281/2,421 Sec#2/96 |
| Value | ||
| P/B | 1.31x | KR#1,688/2,421 Sec#57/96 |
| P/S | 1.46x | KR#1,622/2,421 Sec#43/96 |
| EV/EBITDA | 55.56x | KR#1,379/2,421 Sec#44/96 |
| FCF Yield | -1.59% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -1.13% | KR#1,631/2,421 Sec#53/96 |
| ROA | -0.69% | KR#1,635/2,421 Sec#55/96 |
| Op. Margin | 3.22% | KR#1,215/2,421 Sec#45/96 |
| Revenue Growth | 6.64% | KR#1,098/2,421 Sec#61/96 |
| Earnings Growth | -550.90% | KR#1,307/2,421 Sec#48/96 |
| Financial Health | ||
| Debt Ratio | 64.61% | KR#1,152/2,421 Sec#65/96 |
| Total Debt | 165.33B KRW | KR#571/2,421 Sec#7/96 |
| FCF | -7.60B KRW | KR#1,619/2,421 Sec#59/96 |
| Cash | 58.64B KRW | KR#674/2,421 Sec#15/96 |
| Current Ratio | 1.76x | KR#996/2,421 Sec#59/96 |
| Net Debt/EBITDA | 10.15x | KR#1,229/2,421 Sec#41/96 |
| Dividend | ||
| Div. Yield | 0.62% | KR#1,228/2,421 Sec#37/96 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/96 |
| Performance | ||
| 1Y Return | -19.21% | KR#1,246/2,421 Sec#27/96 |
| 1M Return | -11.84% | KR#2,165/2,421 Sec#80/96 |
| From 52W High | -41.49% | KR#991/2,421 Sec#30/96 |
| 1Y MDD | -45.59% | KR#792/2,421 Sec#23/96 |
| Trading | ||
| Volume | 31,997 shares | KR#1,349/2,421 Sec#47/96 |
| Trading Value | 515.3M KRW | KR#914/2,421 Sec#26/96 |
| Foreign Own. | 24.84% | KR#167/2,421 Sec#4/96 |
| Per Share | ||
| EPS | -139 KRW | KR—/2,421 Sec—/96 |
| BPS | 12,308 KRW | KR#834/2,421 Sec#16/96 |
Company Info
Established in 2000, this company develops, manufactures, and sells medical sensors and measuring instruments using electrochemical and biosensor technologies. Its blood glucose meter segment, including self-monitoring and continuous glucose monitoring systems, accounts for over 80% of sales, while the point-of-care testing (POCT) segment for critical care analysis equipment contributes 10%. The company holds world-leading technology for blood sample volume (0.5㎕) and measurement speed (5 seconds), expanding global market share with the domestic launch of CareSens Air, the first continuous glucose monitoring system in Korea. i-SENS is headquartered in Seocho-gu, Seoul.